Topic
Hepatocellular Carcinoma (HCC)
77 Podcasts • 47 Cases • 7 Courses on BackTable
Hear how experienced physicians manage Hepatocellular Carcinoma (HCC) on BackTable. Learn from podcasts, cases, and courses curated by physician content creators, covering diagnosis, clinical decision-making, and treatments. Get the BackTable app to follow this Topic and hear more of the conversations that matter to your practice.
Episode # 72 • 14 Jul 2026
Optimizing Liver-Directed Interventions for Neuroendocrine Tumors
What factors come into play when deciding whether to use liver-directed therapy or systemic therapies for neuroendocrine tumors? In this episode of the BackTable Tumor Board Podcast, Dr. Lingling Du, Dr. Chih-Yi Liao, and Dr. Abdul Khan discuss the structure of a multidisciplinary tumor board and how they approach decision-making for patients with neuroendocrine tumors. The conversation explores who benefits most from liver-directed therapy, optimal timing for intervention, and the importance of individualized treatment planning.
More on Hepatocellular Carcinoma (HCC)
Loading recent podcasts…
Tumor Board # 72
Jul 14, 2026
with Dr. Chih-Yi Liao, Dr. Abdul Khan, Dr. Lingling Du
What factors come into play when deciding whether to use liver-directed therapy or systemic therapies for...
10+ listens
Vascular & IR # 659
Jun 30, 2026
with Dr. Beau Toskich, Dr. Lingling Du, Dr. Tyler Sandow
How do you safely combine locoregional and systemic therapies to treat hepatocellular carcinoma (HCC) when traditional...
1,000+ listens
Vascular & IR # 655
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone, Dr. Zach Berman
How is Y90 radioembolization rewriting the rules for managing large HCC tumors and creating new curative-intent...
1,500+ listens
Vascular & IR # 651
Jun 2, 2026
with Dr. Kirema Garcia-Reyes, Dr. Zach Berman, Dr. Nima Kokabi
What does it really take to run a high-volume Y90 program that is efficient, scalable, and patient-centered? In this...
1,300+ listens
Vascular & IR # 660
Jul 3, 2026
with Dr. David Madoff, Dr. Michael Barraza
How is portal vein embolization (PVE) pushing the boundaries of liver tumor resectability, and what does it take to...
1,200+ listens
Vascular & IR # 657
Jun 23, 2026
with Dr. Beau Toskich, Dr. Juan Gimenez, Dr. Tyler Sandow
What do you do when Y-90 doesn’t deliver the results you expected? In this episode of the 2026 HCC Creator Weekend™,...
1,300+ listens
Vascular & IR # 653
Jun 9, 2026
with Dr. Beau Toskich, Dr. Christopher Malone, Dr. Venkatesh Krishnasamy
How can targeted liver radiation unlock surgical or transplant options for tough hepatocellular carcinoma (HCC) cases?...
1,400+ listens
Vascular & IR # 649
May 27, 2026
with Dr. Nima Kokabi, Dr. Riad Salem, Dr. Zach Berman
Can the right dosimetry approach turn palliative Y90 into a curative therapy? In this episode of the BackTable 2026 HCC...
1,300+ listens
VI Case
Jul 28, 2026
with Dr. Trushar Patel and Dr. Sabeen Dhand
VI Case
Apr 30, 2026
with Dr. Christopher Malone, Dr. Kirema Garcia-Reyes and Dr. Venkatesh Krishnasamy
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.